Ozenoxacin

Ozenoxacin is a quinolone antibiotic. It is active against clinical isolates of S. pyogenes, P aeruginosa, and P. acnes and clinical isolates of antibiotic-sensitive and -resistant S. aureus, S. epidermidis, and S. pneumoniae (MIC50s = 0.00625-1.56 mg/L). Ozenoxacin inhibits S. aureus DNA gyrase and topoisomerase IV (IC50s = 4.5 and 0.617 mg/L, respectively). It reduces insulin- or 5alpha-dihydroxy testosterone-induced triglyceride production and lipid droplet formation in primary hamster sebocytes when used at a concentration of 30 µM. Ozenoxacin (30 µg/ml) decreases heat-killed C. acnes-induced increases in IL-6 and IL-8 production in HEKa primary human keratinocytes and IL-1beta, IL-6, IL-8, and TNF-alpha production in THP-1 monocytes. Topical application of ozenoxacin (1%) decreases skin lesion bacterial counts in a mouse model of burn infection caused by S. aureus. Formulations containing ozenoxacin have been used in the treatment of S. aureus- or S. pyogenes-associated impetigo.Formal Name: 1-cyclopropyl-1,4-dihydro-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-3-quinolinecarboxylic acid. CAS Number: 245765-41-7. Synonyms: T-3912. Molecular Formula: C21H21N3O3. Formula Weight: 363.4. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMSO: Slightly soluble: 0.1-1 mg/ml. SMILES: O=C(C1=CN(C2CC2)C3=C(C)C(C4=CC(C)=C(NC)N=C4)=CC=C3C1=O)O. InChi Code: InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27). InChi Key: XPIJWUTXQAGSLK-UHFFFAOYSA-N.